Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Clin Lab Int. Author manuscript; available in PMC 2017 August 15.
Published in final edited form as:
PMCID: PMC5556939

Point-of-Care Molecular Test for Zika Infection


The recent outbreak of Zika virus (ZIKV) infection has led to a serious threat to public health. Rapid and sensitive diagnostics for ZIKV infection are crucial because Zika infection is usually mild and often asymptomatic, but may have serious consequences to infants born to infected mothers. We report on a simple, sensitive, inexpensive, point-of-care (POC) diagnostic technology for rapid detection of ZIKV in saliva. We use a chemically heated cup for isothermal amplification without a need for electrical power. The detection results can be directly read out by eye.


The recent emergence of the Zika virus pandemic has underscored the need for point-of-care (POC) test that can detect viral infections, fostering widespread, accurate, and timely diagnostics [1,2]. Zika infection is often asymptomatic or has comparatively mild symptoms such as fever and chills that are common to many other infections, but as is widely known, Zika infection during pregnancy entails substantial risks for the newborn, including severe birth defects [3]. Hence, it is highly desirable to screen women of child-bearing age and their partners to exposure to the Zika virus. Zika episodes have created bottlenecks in conventional laboratory-based diagnostic.

Zika is spread primary by mosquitos, but sexual and perinatal transmission, and transmission via blood transfusions have also been reported. Specific applications for Zika diagnostics thus include determining whether infection has occurred over the course of a pregnancy, whether sexual partners harbor infection, safeguarding the blood supply, and tracking the geographic range of Zika infections [4]. In order to inform investment decisions on prevention, control and response, Lee et al. [5] modeled the economic burden for various scenarios of Zika emergence across six US states, estimating total costs (direct medical, Medicaid, productivity losses) ranging from 0.5 to 2 billion dollars.

Ideally, a POC technology will enable rapid diagnostics tests that can be performed outside of centralized laboratories such as, for example, in doctors or dentists offices, pharmacies, rural clinics, school infirmaries, border crossings, or ultimately, as an over-the-counter test for home use. Thus, the availability of a mass-produced, inexpensive POC diagnostics device with easy-to-interpret test results, and that could be used in any almost any locale by non-specialists with minimal training, would greatly expand capabilities and options for screening, surveillance, diagnostics, monitoring, and therapy.

Current diagnostics technology

According to the WHO, the pipeline diagnostic ZIKV kits can be categorized into: (i) antibody/antigen-based immunoassay and (ii) nucleic acid-based molecular diagnostics [6]. Immunoassay (antibody detection) for ZIKV infection utilizes envelope proteins and NS1 as targets. The major challenge is that these antibodies cross-react with other highly homologous flaviviruses such as dengue, resulting in non-specific test results [7]. IgM and IgG antibodies, typically emerge, respectively, ~ 4 and ~10 days after infection, but are usually undetectable until >7–14 days post infection. Moreover, antibody responses during pregnancy may differ from those in non-pregnant individuals [8], which may adversely impact the effectiveness of immunoassay tests. Moreover, antibody tests may not discriminate between recent and long ago exposure. The Food and Drug Administration (FDA) recently authorized for emergency use of the IgM Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA) to detect ZIKV [8]. However, this assay requires a lab-format with delays in generating results given current demand. More importantly, these assays are a readout for exposure to Zika virus, whereas active virus infection is not determined. Currently, several companies are developing lateral flow-based rapid diagnostic test for ZIKV antibody detection [9,10].

Molecular diagnostics-based on RT-PCR is highly specific and sensitive, and considered the “gold standard” for ZIKV detection. RT-PCR is effective in serum, semen, and saliva within <14 days post infection, and possibly much longer in urine and semen [11, 12]. Importantly, a recent study has demonstrated that ZIKV is detectable in pregnant women throughout their pregnancy [13]. Indeed, the FDA has authorized the use of the Trioplex rRT-PCR laboratory test to detect Zika virus, dengue virus, and chikungunya virus RNA, under an Emergency Use Authorization (EUA) [14]. Several research groups and companies are developing multiplexed molecular assays to concurrently detect various members of the genus flavivirus. Most of these RT-PCR kits require, however. Instrumentation and are for central laboratory use.

Instrument-free point-of-care molecular detection of Zika virus

To develop inexpensive molecular detection of ZIKV without complex instrumentation, we utilized reverse-transcription loop-mediated amplification (RT-LAMP) technology [15]. We identified highly conserved regions of the ZIKV genome and designed RT-LAMP primers for the Zika lineage that is prevalent in the Americas. To enable POC molecular diagnostics, we developed a disposable microfluidic cassette (Fig. 1A) that combines viral nucleic acid capture, concentration, isothermal amplification; and detection. Our disposable, microfluidic cassette contains multiple independent amplification reactors, each equipped with a silica-based nucleic acid isolation membrane at its inlet. The advantage of such a design is to decouple the sample volume from the reaction volume, allowing one to use relatively high sample volumes to achieve high sensitivity. Nucleic acids captured by the isolation membrane directly serve as templates in an RT-LAMP amplification process without a need for an elution step, significantly simplifying flow control.

Figure 1
(A) Photograph of integrated microfluidic cassette for point of care molecular diagnostics of ZIKV. (B) Photograph of the chemically heated cup for on-chip isothermal amplification. (C) Photograph of the isothermal amplification reactors after 40 min ...

Our microfluidic cassette can be incubated with battery power or operate electricity-free. To eliminate the need for electricity, we used a simple, thermally insulated portable cup (Fig. 1B) heated by an exothermic reaction for chip-based isothermal amplification [15]. One Mg–Fe alloy pouch, which is usually used as a heater of MRE (meal, ready-to-eat), served as the heat source. Tap water was introduced into the drawer, housing the Mg-Fe pouch, through a port in the cup lid to interact with the Mg–Fe alloy to produce heat. To isolate the amplification reactors’ temperature from variable ambient conditions, we used a phase change material (PCM) to regulate the temperature, removing the need for a thermal control circuit. An aluminum heat sink was used to enhance heat transfer from the PCM to the cassette.

We tested the utility of our POC diagnostic system with raw saliva samples spiked with various concentrations of the ZIKV. Our experiments showed that our electricity-free POC diagnostic system could detect ZIKV in saliva with the sensitivity of 5 PFU of ZIKV per sample within 40 min (Fig. 1C). Our POC diagnostic system is comparable to that of the benchtop assay without a need for laboratory facilities, expensive equipment, and well-trained personnel [15].


Zika molecular diagnostics can be performed at the point of care with a low-cost, portable system based on a microfluidic cassette that integrates nucleic acid isolation and concentration, isothermal amplification, and detection. To achieve electricity-free isothermal amplification, the cassette is combined with a chemically-heated cup that generates heat with an exothermic reaction. The platform can be adapted to various sample types and sizes, and multiplex detection. This flexibility is useful in view of the evolving understanding of Zika pathology and Zika biomarker levels and their persistence in different body fluids and tissues. In the future, we plan to expand system capabilities to enable concurrent detection of multiple vector-borne diseases [16]. Our system is very suitable for resource-poor settings, where funds, centralized laboratory facilities, and trained personnel are in short supply, and for use in remote clinics, and at home.


The research reported here was supported, in part by the NIH NIDCR R21DE026700, K25AI099160, R01 CA214072, to the University of Pennsylvania.


1. Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, Dub T, Baudouin L, Teissier A, Larre P, Vial AL. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. The Lancet. 2016;387(10027):1531–1539. [PMC free article] [PubMed]
2. Tang H, Hammack C, Ogden SC, Wen Z, Qian X, Li Y, Yao B, Shin J, Zhang F, Lee EM, Christian KM. Zika virus infects human cortical neural progenitors and attenuates their growth. Cell stem cell. 2016;18(5):587–590. [PMC free article] [PubMed]
3. Driggers RW, Ho CY, Korhonen EM, Kuivanen S, Jääskeläinen AJ, Smura T, Rosenberg A, Hill DA, DeBiasi RL, Vezina G, Timofeev J. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. New England Journal of Medicine. 2016;374:2142–2151. [PubMed]
4. Kindhauser MK, Allen T, Frank V, Santhana RS, Dye C. Zika: the origin and spread of a mosquito-borne virus. Bull World Health Organ. 2016;94:675–686C. [PMC free article] [PubMed]
5. Lee BY, Alfaro-Murillo JA, Parpia AS, Asti L, Wedlock PT, Hotez PJ, Galvani AP. The potential economic burden of Zika in the continental United States. PLOS Neglected Tropical Diseases. 2017;11(4):e0005531. [PMC free article] [PubMed]
6. WHO. Current Zika Product Pipeline., Viewed May 20, 2017.
7. Charrel RN, Leparc-Goffart I, Pas S, de Lamballerie X, Koopmans M, Reusken C. State of knowledge on Zika virus for an adequate laboratory. Viewed May 20, 2017.
8. New CDC Laboratory Test for Zika Virus Authorized for Emergency Use by FDA., Viewed May 20, 2017.
9. Zika Rapid Test, Biocan Diagnostics Inc., Viewed May 20, 2017.
10. ARTRON Zika Test, Artron Laboratories Inc. Viewed May 20, 2017.
11. Gourinat AC, O’Connor O, Calvez E, Goarant C, Dupont-Rouzeyrol M. Detection of Zika virus in urine. Emerging infectious diseases. 2015;21(1):84. [PMC free article] [PubMed]
12. Mansuy JM, Dutertre M, Mengelle C, Fourcade C, Marchou B, Delobel P, Izopet J, Martin-Blondel G. Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen. Lancet Infect Dis. 2016;16:405. [PubMed]
13. Driggers RW, Ho CY, Korhonen EM, Kuivanen S, Jääskeläinen AJ, Smura T, Rosenberg A, Hill DA, DeBiasi RL, Vezina G, Timofeev J. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. New England Journal of Medicine. 2016;374:2142–51. [PubMed]
14. Trioplex Real-time RT-PCR Assay, Centers for Disease Control and Prevention. Viewed May 20, 2017.
15. Song J, Mauk MG, Hackett BA, Cherry S, Bau HH, Liu C. Instrument-free point-of-care molecular detection of Zika virus. Analytical Chemistry. 2016;88:7289–7294. [PMC free article] [PubMed]
16. Song J, Liu C, Mauk MG, Rankin SC, Lok JB, Greenberg RM, Bau HH. Two-Stage Isothermal Enzymatic Amplification for Concurrent Multiplex Molecular Detection. Clinical Chemistry. 2017 clinchem-2016. [PubMed]